Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Ontology highlight
ABSTRACT: Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
PROVIDER: PRJNA498500 | ENA |
REPOSITORIES: ENA
ACCESS DATA